Once-daily, subcutaneous injection that can be administered at home1
Titrate patients to the maintenance dose to optimize efficacy and tolerability
- IMCIVREE should be administered once daily, at the beginning of the day, without regard to meals1
- There is no food requirement for administration1
- No dose adjustments are needed for patients with mild to moderate renal impairment1
IMCIVREE dosage in patients with renal impairment1
Recommended dosage in patients with severe renal impairment (eGFR of 15 to 29 mL/min/173 m2)
For patients aged 2 to <6 weighing at least 20 kg with severe renal impairment1:
- The recommended starting dosage is 0.5 mg (0.05 mL) injected subcutaneously once daily for 2 weeks in pediatric patients aged 2 to less than 6 years with severe renal impairment and weight at least 20 kg
- The use of IMCIVREE in pediatric patients aged 2 to less than 6 years with weight less than 20 kg and severe renal impairment is not recommended
- Monitor patients for GI adverse reactions during dosage initiation and titration
- If the recommended starting dosage is:
- Not tolerated; discontinue IMCIVREE
- Tolerated for 2 weeks; increase the dosage based on baseline body weight, as presented in the table below
- The recommended maintenance dosage is 1 mg (0.1 mL) injected subcutaneously once daily. Monitor patients for adverse reactions
For patients aged 6 to <12 with severe renal impairment1:
- The recommended starting dosage is 0.5 mg (0.05 mL) injected subcutaneously once daily for 2 weeks in pediatric patients aged 6 to less than 12 years with severe renal impairment
- Monitor patients for GI adverse reactions during dosage initiation and titration
- If the recommended starting dosage is:
- Not tolerated; discontinue IMCIVREE
- Tolerated for 2 weeks; increase the dosage to 1 mg (0.1 mL) injected subcutaneously once daily. The recommended maintenance dosage is 1 mg (0.1 mL) injected subcutaneously once daily
For patients aged ≥12 with severe renal impairment1:
- The recommended starting dosage is 0.5 mg (0.05 mL) injected subcutaneously once daily for 2 weeks in adults and pediatric patients aged 12 years and older with severe renal impairment
- Monitor patients for GI adverse reactions during dosage initiation and titration
- If the recommended starting dosage is:
- Not tolerated; discontinue IMCIVREE
- Tolerated for 2 weeks; increase the dosage to 1 mg (0.1 mL) once daily. If the 1 mg daily dosage is tolerated for at least 1 week, increase the dosage to 1.5 mg (0.15 mL) once daily. The recommended maintenance dosage is 1.5 mg (0.15 mL) injected subcutaneously once daily
There is no recommended dosage change in patients with mild or moderate renal impairment1
- The recommended dosage in patients with mild renal impairment (eGFR of 60 to 89 mL/min/1.73 m2) or moderate renal impairment (eGFR of 30 to 59 mL/min/1.73 m2) is the same as in those with normal kidney function
IMCIVREE is not recommended for use in patients with end-stage renal disease (eGFR less than 15 mL/min/1.73 m2)1
eGFR=estimated glomerular filtration rate; GI=gastrointestinal.
Reference: 1. IMCIVREE [prescribing information]. Boston, MA. Rhythm Pharmaceuticals, Inc.
10-mg/1-mL
multiple-dose vial
Effective, long-term weight management starts with setting patient expectations
Achieving the benefits of treatment with IMCIVREE may take time
In clinical trials, it took some time for hunger and weight reductions to occur, while patients experienced certain AEs soon after starting treatment. This chart highlights some of the most common AEs, but it does not include all reported AEs.
- Meaningful weight reduction began within 6-8 weeks and continued over time 1-5
- Hunger reduction began within weeks. Measures of hunger increased quickly upon dose reduction or discontinuation of IMCIVREE1-3,6
- Nausea and vomiting were primarily reported within the first 4 weeks of treatment and typically resolved within a few days; nearly all events were mild and none were serious2,3,5,6
- Hyperpigmentation typically occurred within 2-3 weeks and increased throughout the dose titration period; levels generally plateaued in the initial months of treatment and were sustained over long-term treatment with IMCIVREE6
Managing patient expectations
In clinical trials:
Talking to patients about when they can expect weight and hunger benefits and common adverse reactions may help them manage through the short-term treatment initiation to achieve their longer-term goals
AE=adverse event.
References: 1. IMCIVREE [prescribing information]. Boston, MA. Rhythm Pharmaceuticals, Inc. 2. Haqq AM et al. Lancet Diabetes Endocrinol. 2022;10(12):859-868. doi:10.1016/S2213-8587(22)00277-7. Supplemental appendix available at: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00277-7/fulltext. 3. Argente J et al. Lancet Diabetes Endocrinol. 2025;13(1):29-37. doi:10.1016/ S2213-8587(24)00273-0. 4. Grossman DC et al; US Preventive Services Task Force. JAMA. 2017;317(23):2417-2426. doi:10.1001/jama.2017.6803 54. 5. Argente J et al. Endocrine Society Annual Meeting. Poster ODP606. June 11-14, 2022. 6. Data on file. Rhythm Pharmaceuticals, Inc. Boston, MA.